HIV-related mechanisms in atherosclerosis and cardiovascular diseases

Journal of Cardiovascular Medicine

Volumn 14, Issue 11, 2013, Pages 780-790

  Gibellini, Davide ^a   Borderi, Marco ^b   Clò, Alberto ^a   Morini, Silvia ^a   Miserocchi, Anna ^a   Bon, Isabella ^a   Ponti, Cristina ^c   Re, Maria Carla ^a,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d National Institute of Biostructure and Biosystems   (Italy)

Author keywords

atherosclerosis; cardiovascular diseases; HIV

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; CD1B ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE C; RANTES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CARTILAGE CELL; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEUKOCYTE; LIPID METABOLISM; MACROPHAGE; MICROVASCULAR ENDOTHELIAL CELL; MONOCYTE; OSTEOBLAST; PATHOGENESIS; PHAGOCYTE; REVIEW; SMOOTH MUSCLE FIBER; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; UPREGULATION;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 84885374903     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283619331     Document Type: Review

References (167)

1. Levy JA. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 2009; 23:147-160.
2. Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS 2009; 23:1297-1310.
3. Joshi VV, Pawel B, Connor E, et al. Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol 1987; 7:261-275.
4. Paton P, Tabib A, Loire R, et al. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993; 144:225-231.
5. Luginbuhl LM, Orav EJ, McIntosh K, Lipshultz SE. Cardiac morbidity and related mortality in children with HIV infection. JAMA 1993; 269:2869-2875.
6. Sims A, Hadigan C. Cardiovascular complications in children with HIV infection. Curr HIV/AIDS Rep 2011; 8:209-214.
7. Le Houssine P, Karmochkine M, Ledru F, et al. Primary pulmonary hypertension in human immunodeficiency virus infection. Study of 9 cases and review of the literature. Rev Med Interne 2001; 22:1196-1203.
8. Mu H, Chai H, Lin PH, et al. Current update on HIV-associated vascular diseases and endothelial dysfunction. World J Surg 2007; 31:632-643.
9. Ho JE, Hsue PY. Cardiovascular manifestations of HIV infection. Heart 2009; 95:1193-1202.
10. Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008; 196:720-726.
11. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intimamedial thickness measurements from the FRAM study. AIDS 2009; 23:1841-1849.
12. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-1067.
13. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
14. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
15. Vittecoq D, Escaut L, Chironi G, et al. Coronary heart disease in HIVinfected patients in the highly active antiretroviral treatment era. AIDS 2003; 17:S70-S76.
16. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471-477.
17. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118:e29-e35.
18. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512.
19. Crowe SM, Westhorpe CLV, Mukhamedova N, et al. The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010; 87:589-598.
20. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
21. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-212.
22. Hansson GK. Inflammation, Atherosclerosis and coronary artery disease. N Eng J Med 2005; 352:1685-1695.
23. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009; 27:165-197.
24. McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 2011; 50:331-347.
25. Thakore AH, Guo CY, Larson MG, et al. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am J Cardiol 2007; 99:1598-1602.
26. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148:209-214.
27. Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 2009; 6:192-199.
28. Kleinbongard P, Heusch G, Schulz R. TNFa in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 2010; 127:295-314.
29. Lei L, Xiong Y, Chen J, et al. TNFa stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J Lipid Res 2009; 50:1057-1067.
30. Molina JM, Scadden DT, Byrn R, et al. Production of tumor necrosis factor a and interleukin 1b by monocytic cells infected with human immunodeficiency virus. J Clin Invest 1989; 84:733-737.
31. Iannello A, Samarani S, Debbeche O, et al. Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J Virol 2009; 83:5999-6010.
32. Herbeuval JP, Boasso A, Grivel JC, et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2005; 105:2458-2464.
33. Gruber MF, Weih KA, Boone EJ, et al. Endogenous macrophage CSF production is associated with viral replication in HIV-1 infected human monocyte-derived macrophages. J Immunol 1995; 154:5528-5535.
34. Ji J, Sahu GK, Braciale VL, Cloyd MW. HIV-1 induces IL-10 production in human monocytes via a CD4-independent pathway. Intern Immun 2005; 17:729-736.
35. Oyaizu N, McCloskey TW, Than S, et al. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-g and tumor necrosis factor-a secretion. Blood 1994; 84:2622-2631.
36. Birx DL, Redfield RR, Tencer K, et al. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990; 76:2303-2310.
37. Buonaguro L, Barillari G, Chang HK, et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992; 66:7159-7167.
38. Scala G, Ruocco MR, Ambrosino C, et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 1994; 179:961-971.
39. Barqasho B, Nowak P, Tjernlund A, et al. QUEST study group: Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption. HIV Med 2009; 10:94-102.
40. Gibellini D, Zauli G, Re MC, et al. Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF-b1 mRNA expression and protein synthesis in peripheral blood monocytes. Br J Haematol 1994; 88:261-267.
41. Cheung R, Ravyn V, Wang L, et al. Signaling mechanism of HIV-1 gp120 and virion-induced IL-1b release in primary human macrophages. J Immunol 2008; 180:6675-6684.
42. Weiss L, Haeffner-Cavaillon N, Laude M, et al. HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 a in vitro. AIDS 1989; 3:695-699.
43. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001; 12:133-150.
44. Lafeuillade A, Poizot-Martin I, Quilichini R, et al. Increased interleukin-6 production is associated with disease progression in HIV infection. AIDS 1991; 5:1139-1140.
45. Torre D, Pugliese A. Interleukin-18: a proinflammatory cytokine in HIV-1 infection. Curr HIV Res 2006; 4:423-430.
46. Ahmad R, Sindhu ST, Toma E, et al. Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis. J Virol 2002; 76:12448-12456.
47. Larranaga GF, Petroni A, Deluchi G, et al. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis 2003; 14:15-18.
48. Ostrowski SR, Katzenstein TL, Pedersen BK, et al. Residual viraemia in HIV-1-infected patients with plasma viral load or 20 copies/ml is associated with increased blood levels of soluble immune activation markers. Scand J Immunol 2008; 68:652-660.
49. Bastard JP, Soulié C, Fellahi S, et al. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther 2012; 17:915-919.
50. Stone SF, Price P, Keane NM, et al. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002; 3:21-27.
51. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990; 144:480-484.
52. Tebas P, Henry WK, Matining R, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One 2008; 3:e2021.
53. Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intimamedia thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 2007; 116:32-38.
54. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175-1182.
55. Corrado E, Rizzo M, Coppola G, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 2010; 17:1-11.
56. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4:361-368.
57. De Lorenzo F, Boffito M, Collot-Teixeira S, et al. Prevention of atherosclerosis in patients living with HIV. Vasc Health Risk Manag 2009; 5:287-300.
58. Chaudhary M, Kashya B, Gautam H, et al. Role of C-reactive protein in HIV infection: a pilot study. Viral Immunol 2008; 21:263-266.
59. Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70.
60. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-273.
61. Almeida M, Cordero M, Almeida J, Orfao A. Abnormal cytokine production by circulating monocytes and dendritic cells of myeloid origin in ART-treated HIV-1 patients relates to CD4 T-cell recovery and HCV co-infection. Curr HIV Res 2007; 5:325-336.
62. Gascon RL, Narvaez AB, Zhang R, et al. Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. J Acquir Immune Defic Syndr 2002; 30:146-153.
63. Pulliam L, Gascon R, Stubblebine M, et al. Unique monocyte subset in patients with AIDS dementia. Lancet 1997; 349:692-695.
64. Trial J, Rubio JA, Birdsall HH, et al. Monocyte activation by circulating fibronectin fragments in HIV-1-infected patients. J Immunol 2004; 173:2190-2198.
65. Hearps AC, Maisa A, Cheng WJ, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young males which persist despite cART. AIDS 2012; 26:843-853.
66. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74:2527-2534.
67. Locher C, Vanham G, Kestens L, et al. Expression patterns of Fc g receptors, HLA-DR and selected adhesion molecules on monocytes from normal and HIV-infected individuals. Clin Exp Immunol 1994; 98:115-122.
68. Thieblemont N, Weiss L, Sadeghi HM, et al. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol 1995; 25:3418-3424.
69. Heine GH, Ulrich C, Seibert E, et al. CD14(\+\+)CD16\+monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int 2008; 73:622-629.
70. Rossen RD, Smith CW, Laughter AH, et al. HIV-1-stimulated expression of CD11/CD18 integrins and ICAM-1: a possible mechanism for extravascular dissemination of HIV-1-infected cells. Trans Assoc Am Physicians 1989; 102:117-130.
71. Stent G, Cameron PU, Crowe SM. Expression of CD11/CD18 and ICAM-1 on monocytes and lymphocytes of HIV-1-infected individuals. J Leukoc Biol 1994; 56:304-309.
72. Ross AC, Armentrout R, O'Riordan MA, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008; 49:499-506.
73. Birdsall HH, Porter WJ, Green DM, et al. Impact of fibronectin fragments on the transendothelial migration of HIV-infected leukocytes and the development of subendothelial foci of infectious leukocytes. J Immunol 2004; 173:2746-2754.
74. Westhorpe CL, Zhou J, Webster NL, et al. Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte derived macrophages. J Leukoc Biol 2009; 85:1027-1035.
75. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nature Rev Immunol 2010; 10:36-46.
76. Shimada K. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circul J 2009; 73:994-1001.
77. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27:451-483.
78. Brown JN, Kohler JJ, Coberley CR, Sleasman JW. Goodenow MM HIV-1 activates macrophages independent of Toll-like receptors. PLoS One 2008; 3:e3664.
79. Porcheray F, Samah B, Leone C, et al. Macrophage activation and human immunodeficiency virus infection: HIV replication directs macrophages towards a pro-inflammatory phenotype while previous activation modulates macrophage susceptibility to infection and viral production. Virology 2006; 349:112-120.
80. Cassol E, Cassetta L, Alfano M, Poli G. Macrophage polarization and HIV-1 infection. J Leukoc Biol 2010; 87:599-608.
81. Chihara T, Hashimoto M, Osman A, et al. HIV-1 Proteins preferentially activate anti-inflammatory M2-Type macrophages. J Immunol 2012; 188:3620-3627.
82. Kanmogne GD, Kennedy RC, Grammas P. Analysis of human lung ECs for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. AIDS Res Hum Retroviruses 2001; 17:45-53.
83. Moses AV, Nelson JA. HIV infection of human brain capillary endothelial cells: implications for AIDS dementia. Adv Neuroimmunol 1994; 4:239-247.
84. Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. Thromb Res 2012; 129:301-308.
85. Da Silva EF, Fonseca FA, França CN, et al. Imbalance between endothelial progenitors cells and microparticles in HIV-infected patients naive for antiretroviral therapy. AIDS 2011; 25:1595-1601.
86. Ullrich CK, Groopman JE, Ganju RK. HIV-1 gp120-and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood 2000; 96:1438-1442.
87. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005; 333:1107-1115.
88. Huang MB, Bond VC. Involvement of protein kinase C in HIV-1 gp120-induced apoptosis in primary endothelium. J Acquir Immune Defic Syndr 2000; 25:375-389.
89. Park IW, Ullrich CK, Schoenberger E, et al. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 2001; 167:2766-2771.
90. Huang MB, Khan M, Garcia-Barrio M, et al. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir Immune Defic Syndr 2001; 27:213-221.
91. Rusnati M, PrestaM. HIV-1 Tat protein and endothelium: From protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002; 5:141-151.
92. Cantaluppi V, Biancone L, Boccellino M, et al. HIV type 1 Tat protein is a survival factor for Kaposi's sarcoma and ECs. AIDS Res Hum Retroviruses 2001; 17:965-976.
93. Kim TA, Avraham HK, Koh YH, et al. HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J Immunol 2003; 170:2629-2637.
94. Sgadari C, Barillari G, Palladino C, et al. Fibroblast Growth Factor-2 and the HIV-1 Tat protein synergize in promoting Bcl-2 expression and preventing endothelial cell apoptosis: implications for the pathogenesis of AIDS-associated Kaposi's sarcoma. Int J Vasc Med 2011; 2011:452729.
95. Klein D, Hohn HP, Kleff V, et al. Vascular wall-resident stem cells. Histol Histopathol 2010; 25:681-689.
96. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964-967.
97. Khurana R, Simons M. Endothelial progenitor cells: precursors for angiogenesis. Semin Thorac Cardiovasc Surg 2003; 15:250-258.
98. Ló pez M, Vispo E, San Román JS, et al. High risk of endothelial dysfunction in HIV individuals may result from deregulation of circulating endothelial cells and endothelial progenitor cells. AIDS Res Hum Retroviruses 2011; 28:656-659.
99. Ergun S, Hohn HP, Kilic N, et al. Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells. Stem Cell Rev 2008; 4:169-177.
100. Pasquinelli G, Pacilli A, Alviano F, et al. Multidistrict human mesenchymal vascular cells: pluripotency and stemness characteristics. Cytotherapy 2010; 12:275-287.
101. Gibellini D, Alviano F, Miserocchi A, et al. HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall derived mesenchymal stem cells. Retrovirology 2011; 8:40.
102. Gibellini D, Miserocchi A, Tazzari PL, et al. Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cells. J Cell Biochem 2012; 113:1132-1141.
103. Krishnaswamy G, Smith JK, Mukkamala R, et al. Multifunctional cytokine expression by human coronary endothelium and regulation by monokines and glucocorticoids. Microvasc Res 1998; 55:189-200.
104. Herbein G, Keshav S, Collin M, et al. HIV-1 induces tumour necrosis factor and IL-1 gene expression in primary human macrophages independent of productive infection. Clin Exp Immunol 1994; 95:442-449.
105. Nordoy I, Aukrust P, Muller F, et al. Abnormal levels of circulating adhesion molecules in HIV-1 infection with characteristic alterations in opportunistic infections. Clin Immunol Immunopathol 1996; 81:16-21.
106. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185:456-462.
107. Francisci D, Giannini S, Baldelli F, et al. HIV type 1 infection, and not shortterm HAART, induces endothelial dysfunction. AIDS 2009; 23:589-596.
108. Dhawan S, Puri RK, Kumar A, et al. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 1997; 90:1535-1544.
109. Cota-Gomez A, Flores NC, Cruz C, et al. The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism. J Biol Chem 2002; 277:14390-14399.
110. Stins MF, Shen Y, Huang SH, et al. Gp120 activates children's brain endothelial cells via CD4. J Neurovirol 2001; 7:125-134.
111. Bragardo M, Buonfiglio D, Feito MJ, et al. Modulation of lymphocyte interaction with endothelium and homing by HIV-1 gp120. J Immunol 1997; 159:1619-1627.
112. Toneatto S, Finco O, Van der Putten H, et al. Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS 1999; 13:2343-2348.
113. Hofman FM, Chen P, Incardona F, et al. HIV-1 tat protein induces the production of interleukin-8 by human brain-derived endothelial cells. J Neuroimmunol 1999; 94:28-39.
114. Park IW, Wang JF, Groopman JE. HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood 2001; 97:352-358.
115. Gariano RF, Rickman LS, Freeman WR. Ocular examination and diagnosis in patients with the acquired immunodeficiency syndrome. West J Med 1993; 158:254-262.
116. Lin H, Chen W, Luo L, et al. Cytotoxic effect of HIV-1 gp120 on primary cultured human retinal capillary endothelial cells. Mol Vis 2011; 17:3450-3457.
117. Pellicelli AM, Palmieri F, Cicalini S, et al. Pathogenesis of HIV-related pulmonary hypertension. Ann NY Acad Sci 2001; 946:82-94.
118. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004; 157:3-10.
119. Oshima T, Flores SC, Vaitaitis G, et al. HIV-1 Tat increases endothelial solute permeability through tyrosine kinase and mitogen-activated protein kinase-dependent pathways. AIDS 2000; 14:475-482.
120. Avraham HK, Jiang S, Lee TH, et al. HIV-1 Tat-mediated effects on focal adhesion assembly and permeability in brain microvascular endothelial cells. J Immunol 2004; 173:6228-6233.
121. Kanmogne GD, Schall K, Leibhart J, et al. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab 2007; 27:123-134.
122. Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 1998; 95:3117-3121.
123. Kelder W, McArthur JC, Nance-Sproson T, et al. b-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 1998; 44:831-835.
124. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and nonmatrix substrates. Cardiovasc Res 2006; 69:614-624.
125. Louboutin JP, Reyes BA, Agrawal L, et al. HIV-1 gp120 upregulates matrix metalloproteinases and their inhibitors in a rat model of HIV encephalopathy. Eur J Neurosci 2011; 34:2015-2023.
126. Lafrenie RM,WahlLM, Epstein JS, et al. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J Immunol 1996; 156:1638-1645.
127. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116:1832-1844.
128. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet 2004; 5:189-218.
129. Ikonen E. Mechanisms of cellular cholesterol transport: defects and human disease. Physiol Rev 2006; 86:1237-1261.
130. Van der Velde AE. Reverse cholesterol transport: from classical view to new insights. World J Gastroenterol 2010; 16:5908-5915.
131. Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res 2009; 50:S15-S27.
132. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006; 26:1702-1711.
133. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 2002; 110:905-911.
134. Fielding CJ, Fielding PE. Cellular cholesterol efflux. Biochim Biophys Acta 2001; 1533:175-189.
135. Qin C, Nagao T, Grosheva I, et al. Elevated plasma membrane cholesterol content alters macrophage signaling and function. Arterioscler Thromb Vasc Biol 2006; 26:372-378.
136. Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res 2009; 50:S382-S387.
137. Brown TT. The effects of HIV-1 infection on endocrine organs. Best Pract Res Clin Endocrinol Metab 2011; 25:403-413.
138. Micheletti RG, Fishbein GA, Fishbein MC, et al. Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study. Cardiovasc Pathol 2009; 18:28-36.
139. Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
140. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metabol 1992; 74:1045-1052.
141. Khovidhunkit W, Memon RA, Feingold KR, et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 181:S462-S472.
142. El-Sadr WM, Mullin C, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005; 6:114-121.
143. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008; 199:79-86.
144. Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metabol 1993; 76:1423-1427.
145. Duong M, Petit JM, Martha B, et al. Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. HIV Clin Trials 2006; 7:41-47.
146. Malvestutto CD, Aberg JA. Coronary heart disease in people infected with HIV. Cleve Clin J Med 2010; 77:547-556.
147. Brown TT. The effects of HIV-1 infection on endocrine organs. Best Pract Res Clin Endocrinol Metab 2011; 25:403-413.
148. Perrin-Cocon L, Coutant F, Agaugue S, et al. Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J Immunol 2001; 167:3785-3791.
149. Morgan MJ, Liu ZG. Reactive oxygen species in TNF a-induced signaling and cell death. Mol Cells 2010; 30:1-12.
150. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006; 72:1493-1505.
151. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4:e365.
152. Bukrinsky M, Sviridov D. HIV and cardiovascular disease: contribution of HIV-infected macrophages to development of atherosclerosis. PLoS Med 2007; 4:e43.
153. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; 4:293-301.
154. Grinspoon S, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
155. Jacobson DL, Knox T, Spiegelman D, et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005; 40:1837-1845.
156. Caron-Debarle M, Lagathu C, Boccara F, et al. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010; 16:218-229.
157. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAARTassociated lipodystrophy. Antivir Ther 2006; 11:729-740.
158. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17:4-12.
159. Boothby M, McGee KC, Tomlinson JW, et al. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther 2009; 14:1089-1100.
160. Otake K, Omoto S, Yamamoto T, et al. HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors. AIDS 2004; 18:189-198.
161. Shrivastav S, Kino T, Cunningham T, et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor g and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol 2008; 22:234-247.
162. Antinori A, Marcotullio S, Ammassari A, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol 2012; 35:113-159.
163. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
164. Lundgren JD, Neuhaus J, Babiker A, et al. SMART Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
165. Gibellini D, Borderi M, Clò A, et al. Antiretroviral molecules and cardiovascular diseases. New Microbiol 2012; 35:359-375.
166. Farrugia PM, Lucariello R, Coppola JT. Human immunodeficiency virus and atherosclerosis. Cardiol Rev 2009; 17:211-215.
167. Triant V. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis 2012; 205:S355-S361.